90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: Utility of pretransplantation biodistribution

Nuclear Medicine Communications

Volumn 35, Issue 11, 2014, Pages 1132-1142

  Matesan, Manuela ^a   Rajendran, Joseph ^a   Press, Oliver W ^a   Maloney, David G ^b   Storb, Rainer F ^a,b   Cassaday, Ryan D ^a   Pagel, John M ^a,b   Oliveira, George ^c   Gopal, Ajay K ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b USA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

111In ibritumomab tiuxetan; 90Y ibritumomab tiuxetan; B cell lymphoma; Biodistribution; Monoclonal antibodies; Radionuclide therapy

Indexed keywords

CD20 ANTIGEN; IBRITUMOMAB TIUXETAN; RITUXIMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; GAMMA CAMERA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LIVER; MALE; MANTLE CELL LYMPHOMA; MULTIMODALITY CANCER THERAPY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SACRUM; SPLEEN; BONE MARROW; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME; WHOLE BODY IMAGING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BONE MARROW; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SACRUM; TISSUE DISTRIBUTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84916625352     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000172     Document Type: Article

References (22)

1. Leukemia and Lymphoma Society. Facts 2010-2011. Available at: http://s3.amazonaws.com/zanran-storage/action.lls.org/ContentPages/116513290.pdf.
2. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, et al. Eight year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111:5530-5536.
3. Ibritumomab tiuxetan. USA/Package insert/Zevalin. Available at: http://patient.cancerconsultants.com/druginserts/Ibritumomab-tiuxetan.pdf. [Accessed 21 December 2001].
4. Hendrix CS, de Leon C, Dillman RO. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Clin J Oncol Nurs 2002; 6:144-148.
5. Witzig TE,White CA, Gordon KI,Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade follicular, or transformed non-Hodgkin lymphoma. J Clin Oncol 2003; 21:1263-1270.
6. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336-4342.
7. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27:766-777.
8. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003; 44:465-474.
9. Wiseman GA, Leigh BR, Dunn WL, Stabin MG, White CA, et al. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharm 2003; 18:253-258.
10. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39:181-194.
11. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advancedstage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med 2009; 50:1837-1843.
12. Chinn PC, Leonard JE, Rosenberg J, Hanna N, Anderson DR. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 1999; 15:1017-1025.
13. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, et al. 90Y-ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118:1132-1139.
14. Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximabrefractory non-Hodgkin lymphoma. Cancer 2002; 94 (Suppl):1349-1357.
15. Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM, et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 2012; 39:512-520.
16. Kylstra JW. Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: meta-analysis of five clinical trials and 9 years of post-approval safety data. Meeting: ASCO Annual Meeting. Chicago, Illinois, 2011. Presenter: Jelle W Kylstra. Session: Lymphoma and plasma cell disorders (General Poster Session).
17. Aricò D, Grana CM, Vanazzi A, Ferrari M, Mallia A, Sansovini M, et al. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution. Cancer Biother Radiopharm 2009; 24:271-275.
18. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40:259-263.
19. Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, et al. High-activity 90Y-ibritumomab-tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin's lymphomas. Br J Haematol 2007; 139:590-599.
20. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum B 1989; 16:553-559.
21. Juweid M, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res 1995; 55:5827s-5831s.
22. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med 2002; 43:1507-1529.